Washington, DCThe field of personalized cancer research and treatment grows with each day. And a new collaboration with Washington's largest biomedical research organization and an international research and biobanking company is contributing to that growth.
Georgetown University Medical Center announced today an agreement with Indivumed GmbH, based in Hamburg, Germany, which provides the foundation for the analysis of complex clinical molecular signatures from cancer patients, enabling researchers and physicians to better diagnose and tailor cancer treatments for individual patients. This arrangement builds upon a one-year agreement currently in place at Georgetown that established a high-quality tumor biobank and clinical database for pancreatic cancer and which now also includes cancer of the breast and colon.
The expanded collaboration will grow to include a clinical database of prostate, glioblastoma and renal cancer. Together, the institutions will work to establish a robust portfolio of research collaborations, supported by a state-of-the-art biobanking infrastructure and protocol, using Indivumed's established scientific approach, and a multidimensional, integrated clinical and molecular database of cancer.
"Integrating scientific, medical, and technological expertise and assets will transform our ability to analyze complex clinical data relating to specific diseases, employing a more comprehensive, system-level approach to how we treat patients," says Howard J. Federoff, MD, PhD, Executive Vice President for Health Sciences at GUMC. "We're starting with cancer, and hope this kind of research will lead to better, more individually targeted treatments."
The agreement will expand upon the Indivumed Biobank protocol already begun at Georgetown University Hospital, expanding the collection, storage, analysis and utilization of biospecimens. This includes prospective and standardized collection of pre-, intra- and post-
|Contact: Laura Cavender|
Georgetown University Medical Center